摘要
目的:观察脂必泰胶囊治疗血脂异常痰瘀互结证的临床疗效,评价其有效性和安全性。方法:选择西安电子科技大学医院内科门诊2018年7月至2019年7月82例血脂异常痰瘀互结证患者,按照随机数字表法分为对照组和观察组,每组41例,对照组给予阿托伐他汀钙治疗,观察组给予脂必泰胶囊治疗。两组治疗前和治疗8周后分别检测血脂指标、肝功能、肾功能变化情况;比较两组治疗前后中医证候疗效、临床症状评分;记录患者是否存在肝区疼痛、肌肉疼痛等不良反应。结果:治疗8周后血脂变化比较,两组患者血清总胆固醇(total cholesterol,TC)、甘油三脂(triglyceride,TG)、低密度脂蛋白胆固醇(lowdensity lipoprotein cholesterol,LDL-C)均较本组治疗前下降,高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)较本组治疗前升高(P<0. 05)。对照组的总有效率90. 24%(37/41),观察组的总有效率92. 68%(38/41),两组比较差异无统计学意义。治疗后两组中医证候积分,两组患者的眩晕、胸闷、头重如裹、胸膈痞满4种常见中医证候积分均较本组治疗前降低(P<0. 05);两组中医证候疗效比较,对照组总有效率87. 80%(36/41),观察组总有效率92. 68%(38/41),两组比较差异无统计学意义;对照组3例出现氨基转移酶不同程度升高,但均未升高正常高限的2倍,观察组1例出现轻度腹胀、恶心,但不影响继续服药。两组患者均未出现肌肉疼痛、肝区疼痛等现象。结论:脂必泰胶囊治疗血脂异常临床疗效可靠,与阿托伐他汀钙在治疗血脂异常方面临床疗效相当,且安全可靠。
Objective: To observe the clinical efficacy of Zhibitai capsule in the treatment of dyslipidemia with phlegm-stasis binding pattern,in order to evaluate its effectiveness and safety. Method:Totally 82 patients of dyslipidemia with phlegm-stasis binding pattern were selected from the outpatient department of internal medicine in Hospital of Xidian University from July 2018 to July 2019. According to the random number table method,they were divided into control group and observation group,with41 cases in each group. Control group was treated with aAtorvastatin calcium,and observation group was treated with Zhibitai capsules. The changes in blood lipid index,liver function and renal function were measured before and after 8-week treatment in two groups,the efficacy on traditional Chinese medicine(TCM)syndromes and clinical symptom scores before and after treatment were compared between two groups,and the adverse reactions,such as liver pain and muscle pain,were recorded among patients. Result: The changes of blood lipids were compared after 8 weeks of treatment,total cholesterol(TC),triglyceride(TG),and low-density lipoprotein cholesterol(LDL-C)were all lower than before,while high-density lipoprotein cholesterol(HDL-C)was increased(P<0. 05),the total effective rate in control group was 90. 24%(37/41),which was 92. 68%(38/41)in observation group,with no significant difference between two groups,in the TCM syndrome scores of two groups before and after treatment,four common TCM syndromes,namely scores dizziness,chest tightness,head heavy as if swathed and chest fullness,were decreased(P<0. 05). In terms of the efficacy of two groups of TCM syndromes,the total effective rate in control group was 87. 80%(36/41),which was 92. 68%(38/41)in observation group,with no statistically significant difference between two groups. Control group had 3 cases of increased transaminase,but none of them beyond 2 times of the normal upper limit,and observation group had1 case of mild abdominal distension and nausea,which did not affect
作者
李平平
李耀辉
LI Ping-ping;LI Yao-hui(Hospital of Xidian University,Xi'an 710071,China;Shaanxi Academy of Traditional Chinese Medicine,Xi'an 710000,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2020年第16期137-141,共5页
Chinese Journal of Experimental Traditional Medical Formulae
基金
陕西省中医药管理局科研课题项目(2019-ZZ-JC006)。
关键词
脂必泰胶囊
阿托伐他汀钙
血脂异常
痰瘀互结证
Zhibitai capsule
atorvastatin calcium
dyslipidemia
phlegm-stasis binding pattern
